Efficacy of α‐glucosidase inhibitors on lipids in NIDDM subjects with moderate hyperlipidaemia
- 1 August 1994
- journal article
- clinical trial
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 24 (S3), 45-49
- https://doi.org/10.1111/j.1365-2362.1994.tb02256.x
Abstract
This paper summarizes literature data concerning the action of acarbose, an alpha-glucosidase inhibitor, on the concentrations of plasma lipids. Clinical trials in which acarbose has been used in the treatment of non-insulin-dependent diabetics have sometimes shown that it reduces serum triglycerides while it has little or no effect on serum cholesterol levels. The results of a randomized double-blind placebo-controlled study lasting 24 weeks are discussed in more detail. Under the controlled conditions, the effects of acarbose treatment on fasting concentrations of cholesterol, HDL-cholesterol, and triglycerides did not reach statistical significance for the entire patient group. However, in the highest tertile of initial cholesterol concentrations acarbose treatment led to significant lowering of the cholesterol concentration and of the total-to-HDL-cholesterol ratio. The most important benefits of acarbose were observed after a test meal given on day 0 and on week 24 of treatment. The triglyceride increment 1 h postprandial was significantly lowered. This was associated by a significant decrease of the insulin increment. Reduction of hyperinsulinaemia appears to be the mechanism by which acarbose treatment can improve plasma lipid concentrations.Keywords
This publication has 21 references indexed in Scilit:
- Therapeutic Potentials of Acarbose as First-Line Drug in NIDDM Insufficiently Treated With Diet AloneDiabetes Care, 1991
- Effects of Acarbose on Serum Lipoproteins in Healthy Individuals during Prolonged Administration of a Fiber-Free Formula DietAnnals of Nutrition and Metabolism, 1989
- AcarboseDrugs, 1988
- The effect of short-term α-glucosidase inhibition on carbohydrate and lipid metabolism in type II (noninsulin-dependent) diabeticsMetabolism, 1987
- Effects of an α-Glucosidase Inhibitor, Acarbose, on Blood Glucose and Serum Lipids in Streptozotocin-Induced Diabetic RatsHormone and Metabolic Research, 1984
- Effects of a glucosidase inhibitor (acarbose, BAY g 5421) on the development of obesity and food motivated behavior in Zucker (fafa) ratsPharmacology Biochemistry and Behavior, 1983
- Inhibition of carbohydrate-induced hypertriglyceridemia by a disaccharidase inhibitorMetabolism, 1981
- The effects of theα-glucosidase inhibitor BAY g 5421 (Acarbose) on postprandial blood glucose, serum insulin, and triglyceride levels: Dose-time-response relationships in manZeitschrift für Die Gesamte Experimentelle Medizin, 1979